Antoine Chagnon
President and Chief Executive Officer
Antoine Chagnon will be available to meet on the following dates:
Monday, May 12, 12:00 pm to 1:00 pm
Wednesday, May 14, 12:00 pm to 1:00 pm
Tuesday May 20, 12:00 pm to 1:00 pm
Professional background
Antoine Chagnon was appointed President and CEO of Lallemand in January 2015, having previously managed a yeast plant in Passau, Germany, and headed the Bio-Ingredients business unit. Before joining, in 2004, the company which has been in his family since 1952, he made his mark at Audi AG, Ingolstadt, and Siemens AG, Munich.
His solid experience in management and corporate strategy, combined with his skills in process optimization and the management of complex systems, come into their own at Lallemand, where the diverse and complex production of micro-organisms represents a daily challenge.
The company
Lallemand is a privately-owned international company headquartered in Canada. It specializes in the development, production and marketing of micro-organisms (yeasts, bacteria, fungi) and their derivatives. Lallemand provides microbiological solutions to dozens of different industries, from human and animal health to nutrition, bakery, oenology, brewing, food ingredients, probiotics and biofuels.
The company, which recently celebrated 100 years of yeast production at its Montreal plant, has 48 production facilities, as well as distribution centers and offices in over 45 countries on five continents.
Expenses related to this virtual initiative are minimal. Nearly all revenues generated are donated to the IRCM Foundation, whose mission is to support basic and clinical research at the Institut de recherches cliniques de Montréal (IRCM).
Researchers at the IRCM, grouped around 4 major themes, are working to deepen our knowledge of almost all the major diseases of our time: cancer, diabetes, cardiovascular, genetic or inflammatory diseases, Alzheimer's and Parkinson's, to name but a few. Physicians at the IRCM Clinic care for patients living with complex or rare diseases that require ultra-specialized follow-up.
